Cesca Therapeutics’ (KOOL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Cesca Therapeutics (NASDAQ:KOOL) in a report published on Wednesday, The Fly reports. The brokerage currently has a $6.50 price target on the biotechnology company’s stock, up from their prior price target of $1.00.

Separately, ValuEngine upgraded Cesca Therapeutics from a hold rating to a buy rating in a report on Tuesday, July 2nd.

Shares of NASDAQ KOOL opened at $2.99 on Wednesday. Cesca Therapeutics has a twelve month low of $2.10 and a twelve month high of $5.25. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.52 and a quick ratio of 0.81. The firm has a 50-day moving average of $3.08 and a two-hundred day moving average of $1.32.

Cesca Therapeutics (NASDAQ:KOOL) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.13. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. The company had revenue of $4.31 million during the quarter, compared to the consensus estimate of $3.40 million. Equities analysts predict that Cesca Therapeutics will post -0.45 earnings per share for the current fiscal year.

Cesca Therapeutics Company Profile

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Recommended Story: Stop Order

The Fly

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.